HCPCS code Q5108: Fulphila injection, per 0.5 mg2026 Medicare rate & RVUs in California

CMS doesn’t publish an office rate for Q5108 in California.

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What Q5108 covers

Q5108 identifies pegfilgrastim-jmdb, marketed as Fulphila, a biosimilar to pegfilgrastim. This long-acting growth factor is typically administered by subcutaneous injection after myelosuppressive chemotherapy to reduce the risk of infection associated with febrile neutropenia. Oncology practices, hospital outpatient departments, and other clinicians administering the drug may report the product code for a covered dose.

CMS assigns this Part B drug code physician fee schedule status E, which excludes it from the physician fee schedule. When Medicare covers the drug, payment is generally made under another method using CMS’s quarterly Average Sales Price drug pricing files; coverage is left to the Medicare contractor’s judgment. Each unit represents 0.5 mg of pegfilgrastim-jmdb, so 6 mg corresponds to 12 units. Q5108 identifies the drug, not the act of administering the injection.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where Q5108 pays more and less in California

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

29 of 29 payment localities

How the Q5108 rate is calculated

Each of Q5108’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for Q5108

Q5108 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

Q5108 compared with similar codes

How to choose

Q5111Udenyca injectionPer 0.5 mg

Q5111 identifies pegfilgrastim-cbqv (Udenyca); Q5108 is specific to pegfilgrastim-jmdb (Fulphila). Match the code to the product administered.

Q5120Pegfilgrastim-bmezPer 0.5 mg

Q5120 identifies pegfilgrastim-bmez. It is a different pegfilgrastim biosimilar from the pegfilgrastim-jmdb identified by Q5108.

Q5122Nyvepria injectionPer 0.5 mg

Q5122 identifies Nyvepria, another pegfilgrastim biosimilar. Q5108 is used for Fulphila.

Q5101Zarxio injectionPer 1 mcg

Q5101 identifies filgrastim-sndz, not pegfilgrastim-jmdb. These are different growth factor products, so code the product actually administered.

Codes related to Q5108

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates